This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


trusted source


Community cancer care linked with poorer outcomes for patients with a common head and neck cancer

Credit: Unsplash/CC0 Public Domain

Care for patients with human papillomavirus (HPV)-related squamous cell cancers of the oropharynx (an area in back of the throat) is shifting toward community cancer centers, but patients treated in this setting may be less likely to survive, according to new research by investigators from the Johns Hopkins Kimmel Cancer Center and its Head and Neck Cancer Center.

The study, published in the JNCI: Journal of the National Cancer Institute, raises concerns about the quality of care that with this type of head and receive outside of .

Patients treated at community cancer centers were less likely to receive care such as surgery recommended by national guidelines and more likely to receive radiation as a primary treatment. Their outcomes suffered as a result.

"The site of care determines and may influence the therapy landscape and survival for these rare head and neck cancer patients in the future," says senior study author Carole Fakhry, M.D., M.P.H., director of the Johns Hopkins Head and Neck Cancer Center.

The oropharynx consists of structures in the back of the throat, including the base of the tongue, tonsils, and soft palate. HPV-related tumors are caused by HPV, the most common sexually transmitted infection in the U.S. There are about 15,000 new cases of oropharyngeal cancer in the U.S. each year, the vast majority of which are HPV-positive.

Fakhry and her colleagues analyzed U.S. National Cancer Database data from more than 20,000 patients with HPV-related oropharyngeal squamous cell cancers who were diagnosed and underwent treatment between 2010 and 2019. They found that most patients—about two-thirds—continue to receive care at academic cancer centers.

However, the proportion receiving care in community cancer centers grew from 24% in 2010 to 36% in 2019. If these trends continue, as many as half of all patients with these rare cancers will be treated at community cancer centers by 2030.

Growing comfort by clinicians at community cancer centers in treating these cancers may explain this trend, Fakhry says. However, the patients receive in community cancer centers and their survival rates are lagging behind those of patients treated at academic cancer centers.

For example, as more patients shift to community-based care, they are receiving nonsurgical radiation-based therapy. The number of patients receiving nonsurgical treatment increased from 62% to 74% during the study period.

Survival among patients treated at community centers versus academic centers has also started to diverge in recent years. Between 2010 and 2013, the for the two types of centers were similar. However, between 2014 and 2017, about 87% of patients treated at academic cancer centers survived, compared with about 81% at community centers, the research found.

These trends have important implications for future care quality, Fakhry says. "Volume at academic centers is important to train the next generation of physicians. Additionally, if radiation is the primary modality of the future in community centers, there may be a greater need for radiation oncologists and the multidisciplinary team, which is critical to the guideline-directed care of these patients," adds Danielle Trakimas, M.D., lead study author and otolaryngology resident at The Johns Hopkins Hospital.

"If patients with these head and neck cancers are less likely to be treated at academic centers, we need to better understand the determinants of differences in survival outcomes."

The study also bolsters evidence that higher-volume treatment centers have better outcomes than lower-volume ones. Academic centers specializing in treating rare head and neck cancers are more likely to offer transoral robotic surgery and may be better equipped to provide multidisciplinary team care and wrap-around services, improving patient outcomes, Fakhry says.

"It raises the question of whether we should focus care for HPV-related oropharyngeal squamous cell carcinomas at high-volume academic centers to optimize care," she says.

More information: Danielle R Trakimas et al, Increasing radiation therapy and lower survival for human papillomavirus–related oropharynx cancer associated with a shift to community cancer center care, JNCI: Journal of the National Cancer Institute (2024). DOI: 10.1093/jnci/djad238

Citation: Community cancer care linked with poorer outcomes for patients with a common head and neck cancer (2024, January 3) retrieved 21 April 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Care at high-volume radiation treatment centers tied to higher survival


Feedback to editors